KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Equity Income (2016 - 2025)

Historic Equity Income for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $2.1 million.

  • West Pharmaceutical Services' Equity Income fell 4615.38% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 2187.5%. This contributed to the annual value of $14.7 million for FY2024, which is 1694.92% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported Equity Income of $2.1 million as of Q3 2025, which was down 4615.38% from $5.0 million recorded in Q2 2025.
  • West Pharmaceutical Services' Equity Income's 5-year high stood at $8.6 million during Q2 2021, with a 5-year trough of $2.0 million in Q4 2024.
  • Its 5-year average for Equity Income is $4.6 million, with a median of $4.6 million in 2022.
  • In the last 5 years, West Pharmaceutical Services' Equity Income soared by 7857.14% in 2021 and then plummeted by 4615.38% in 2025.
  • West Pharmaceutical Services' Equity Income (Quarter) stood at $6.5 million in 2021, then plummeted by 50.77% to $3.2 million in 2022, then grew by 3.12% to $3.3 million in 2023, then tumbled by 39.39% to $2.0 million in 2024, then rose by 5.0% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $5.0 million for Q2 2025, and $3.4 million during Q1 2025.